# A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

> **NCT02053636** · PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 76 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** lucitanib

## Key facts

- **NCT ID:** NCT02053636
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-03
- **Final completion:** 2017-04-04
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2024-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02053636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02053636, "A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02053636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*